Delivering a gene therapy to market requires a comprehensive and integrated approach. At the 4th annual Gene Therapy for Rare Disorders Conference, Precision ADVANCE participated in a panel discussion, and Precision for Medicine held two clinical presentations, providing crucial insights for clinical development, manufacturing, and commercialization of gene therapies.

On February 23, 2021, Precision ADVANCE’s Anshul Mangal moderated “Considerations for Early-Stage Gene Therapy Start-Ups: From Clinical Development to Manufacturing to Commercialization,” at the Gene Therapy for Rare Disorders virtual conference. ¬†Project Farma’s Tony Khoury and Precision’s Philip Cyr and David Parker joined a panel of industry experts for an update on the status of their current pipelines and development process, as well as a discussion of their unique experiences leading early stage gene therapy companies, the challenges they faced and lessons learned.

To watch the on-demand video of the ADVANCE panel presentation, please click here!

The following day, Precision for Medicine’s Deborah Phippard presented “Planning for Success: Development of Diagnostic Assays for Gene Therapies”, where she provided real-world insights leading to successful development of gene therapy assays. Kristin Ingrassia also presented “Challenges and Mitigations in Gene Therapy Rare Disease Trial Feasibility and Start-up” where she shared best practices for starting up a gene therapy study. Both presentations also discussed more about¬†Precision ADVANCE, interconnected services from Precision for Medicine, Project Farma and Precision Value & Health focused on conquering the complexities of bringing a gene therapy from lab to market.

To watch a video of Deborah’s clinical presentation, click here!

To watch a video of Kristin’s clinical presentation, click here!